A shadow market for unapproved slimming medications is being driven by social media fitness personalities and sellers on messaging platforms, according to recent findings.
Investigational Drug Gaining Popularity Online
The experimental drug, which is still in clinical trials, is being advertised by online personalities for its supposed fat-burning effects. Viewers are urged to message these accounts privately for source information, while also receiving promotional offers.
Active Trade on Messaging Platforms
Additionally, a robust trade exists on Telegram, where communities with thousands of members share “before and after” photos, administration instructions and assertions of rapid UK delivery. Vendors promote the substance there before redirecting customers to WhatsApp for purchases.
Learning About The Experimental Drug
This medication is an experimental injectable created by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could assist individuals reduce up to 25% of their body weight. Referred to as the “triple G”, the substance is being promoted online as the successor to Ozempic.
Medical Professionals Express Concerns
Nevertheless, physicians and pharmacists have warned that the distribution of what remains an unapproved medication in the United Kingdom is a cause for concern and could lead to users administering substances of unknown origin.
Several experts said the demand for retatrutide could be linked to the increasing price of approved slimming products such as Mounjaro.
Regulatory Position and Enforcement
Selling the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unlicensed medication that must not be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.
Some content creators try to circumvent the regulations by referring to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted substance, but advertising and supply can still violate medicines, marketing, and consumer laws, risking penalties, prosecution or imprisonment.
Service Reaction and Material Removal
Based on the social media company, the service has removed problematic content and banned associated keywords and search suggestions. The company stated it was committed to maintaining the platform safe and allocating resources in strengthening enforcement strategies.
Online Marketplace Operations
Research also discovered communities with up to 9,000 participants marketing the experimental drug using Telegram's integrated search feature, which operates like a public directory. Entering “retatrutide” instantly brings up groups with thousands of users, populated with images of slimming results, positive testimonials and step-by-step instructions for mixing or injecting at home.
Within moments of joining one group, a seller posted contact information, where the majority of transactions take place. The vendor sent an guidebook and guaranteed delivery within two days. When asked whether the product was genuine, one seller responded: “You can’t be sure.” Another shared a photo of a alleged testing documentation. None inquired about weight, health issues or previous experience.
Item Details and Costs
Inside these groups, posts display black plastic parcels with postal service labels, claiming to include fresh supplies. One message read: “It took eight of us to load them this morning.”
Buyers can choose between powder vials, mixed at home with sterile water, or ready-to-use pens typically priced at 160 pounds for 20 milligrams. When questioned how long a injector should last, sellers give contradictory responses ranging from a few weeks to “depends on your body”.
Service Oversight and Security Actions
A spokesperson for the messaging service stated it actively moderated harmful material on its service including content that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.
Medical Professional Warnings
“Individuals are administering substances they can’t verify. Although the science behind retatrutide is sound, these digital versions may not contain what they advertise,” said a pharmacy expert, the head of pharmacy at Chemist4U.
A medical professional of an online medical service linked the surge in demand to recent cost increases for authorized weight-loss drugs such as Mounjaro. “With costs rising, individuals are turning to social media. But fake injections are highly risky. You can’t be certain what’s contained or whether the conditions they were made in was sterile,” she explained.
Her team has already encountered patients injured by self-injection from unverified sources. “We understand the disappointment, but purchasing from Telegram or WhatsApp is gambling with your health,” stated the doctor. “These materials could be contaminated or incorrectly dosed.”
Manufacturer Position
A representative from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been reviewed or authorized by any government authority globally. “Consequently at this time no one can sell [it] for personal consumption,” they explained, adding that any product “falsely representing itself as a company investigational substance not yet approved … may subject patients to potentially significant medical dangers”.
